What is the current valuation of the Chemotherapy Market as of 2024?

The Chemotherapy Market was valued at 9.55 USD Billion in 2024. Read More

What is the projected market valuation for the Chemotherapy Market in 2035?

The Chemotherapy Market is projected to reach 20.99 USD Billion by 2035. Read More

What is the expected CAGR for the Chemotherapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Chemotherapy Market during the forecast period 2025 - 2035 is 7.42%. Read More

Which drug class segment is projected to have the highest valuation by 2035?

The Antimetabolites segment is projected to reach 5.75 USD Billion by 2035. Read More

How does the valuation of Breast Cancer treatment compare to Lung Cancer treatment in 2035?

By 2035, Breast Cancer treatment is projected to be valued at 4.25 USD Billion, while Lung Cancer treatment is expected to reach 4.75 USD Billion. Read More

What are the projected valuations for the Intravenous and Oral routes of drug administration by 2035?

The Intravenous route is projected to reach 7.5 USD Billion, while the Oral route is expected to reach 4.5 USD Billion by 2035. Read More

Which end-user segment is anticipated to dominate the Chemotherapy Market by 2035?

The Hospitals & Clinics segment is anticipated to dominate with a projected valuation of 12.54 USD Billion by 2035. Read More

What is the projected valuation for the Alkylating Agents segment by 2035?

The Alkylating Agents segment is projected to reach 5.0 USD Billion by 2035. Read More

Which key players are leading the Chemotherapy Market?

Key players in the Chemotherapy Market include Roche, Bristol-Myers Squibb, Merck & Co., Novartis, and Pfizer. Read More

What is the expected growth trend for the Colorectal Cancer treatment segment by 2035?

The Colorectal Cancer treatment segment is projected to grow to 3.25 USD Billion by 2035. Read More

Chemotherapy Market (2026 - 2035)

Chemotherapy Market Research Report Information By Drug Class (Mitotic Inhibitors, Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), By Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and By End-User (Specialty Centers and Hospitals & Clinics), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Forecast Till 2035

Forecast Period

2026-2035

CAGR

10.21%

2025 Market Size

USD 32.18 Billion (2025)

2035 Market Size

USD 80.45 Billion (2035)

Pharmaceutical ● Updated August 31, 2026 Report ID: MRFR/Pharma/4335-CR | Pages: 126 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Rising Global Cancer Incidence | |
  2. 3.1.2 Biosimilar Cost Reductions for Platinum-Based Cancer Drugs | |
  3. 3.1.3 Oral Formulation Approvals Broadening Cytotoxic Drug Therapy Access | |
  4. 3.1.4 Government Oncology Funding Programs | |
  5. 3.1.5 Fixed-Dose Combination Antineoplastic Treatment Regimens | |
  6. 3.1.6 Expansion of Oncology Drug Infusion Centers | |
  7. 3.1.7 Geriatric Population Growth |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Drug Shortages for Legacy Cytotoxic Agents | |
  2. 3.2.2 Competitive Budget Diversion to Immuno-Oncology | |
  3. 3.2.3 Stricter Hazardous-Waste Disposal Regulations | |
  4. 3.2.4 Adverse-Event Burden Limiting Dose Intensity | |
  5. 3.2.5 API Supply-Chain Concentration Risk |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Antibody–Drug Conjugate Hybrid Regimens | |
  2. 3.3.2 Emerging-Market Cancer-Center Build-Outs | |
  3. 3.3.3 AI-Optimized Dosing and Treatment Scheduling | |
  4. 3.3.4 Oral Chemotherapy Home-Delivery Platforms | |
  5. 3.3.5 Biosimilar Portfolio Expansion in Asia-Pacific |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Chemotherapy Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Drug Class | |
  1. 5.1.1 Alkylating Agents | |
  2. 5.1.2 Antimetabolites | |
  3. 5.1.3 Plant Alkaloids | |
  4. 5.1.4 Antitumor Antibiotics | |
  5. 5.1.5 Others (Platinum Compounds, Miscellaneous) |
2. 5.2 By Route of Administration | |
  1. 5.2.1 Oral | |
  2. 5.2.2 Intravenous | |
  3. 5.2.3 Others (Intrathecal, Intravesical) |
3. 5.3 By Indication | |
  1. 5.3.1 Blood Cancers | |
  2. 5.3.2 Breast Cancer | |
  3. 5.3.3 Lung Cancer | |
  4. 5.3.4 Others (Colorectal, Ovarian, Gastric) |
4. 5.4 By Age Group | |
  1. 5.4.1 Adults (18–64) | |
  2. 5.4.2 Geriatric (65+) | |
  3. 5.4.3 Pediatric (<18)
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 F. Hoffmann-La Roche | |
  2. 7.3.2 Pfizer Inc. | |
  3. 7.3.3 Bristol-Myers Squibb | |
  4. 7.3.4 Novartis AG | |
  5. 7.3.5 Teva Pharmaceutical | |
  6. 7.3.6 Cipla Ltd. | |
  7. 7.3.7 Sun Pharmaceutical | |
  8. 7.3.8 Mylan (Viatris) | |
  9. 7.3.9 Eli Lilly & Co. | |
  10. 7.3.10 Fresenius Kabi
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Precision Dosing |
2. 8.2 Oral Chemotherapy as Default First-Line Modality |
3. 8.3 Supply-Chain Regionalization and API Sovereignty |
4. 8.4 ESG Reporting and Green Chemistry in Cytotoxic Manufacturing
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Chemotherapy Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Chemotherapy Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis — Chemotherapy Market, 2026–2035 |
TABLE 4 Restraint Impact Analysis — Chemotherapy Market, 2026–2035 |
TABLE 5 Regional Market Share Summary — Chemotherapy Market, 2025 |
TABLE 6 North America Chemotherapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Chemotherapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Chemotherapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Chemotherapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Chemotherapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Chemotherapy Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 12 Global Chemotherapy Market Size, by Route of Administration, 2021–2035 (USD Billion) |
TABLE 13 Global Chemotherapy Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 14 Global Chemotherapy Market Size, by Age Group, 2021–2035 (USD Billion) |
TABLE 15 Competitive Benchmarking Matrix — Global Chemotherapy Market, 2025 |
TABLE 16 Company Profiles — Key Players, Global Chemotherapy Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 Report Scope & Methodology Summary |
TABLE 19 Detailed Sources and Citations
13 LIST OF FIGURES |
FIGURE 1 Chemotherapy Market Dynamics — Drivers, Restraints, and Opportunities |
FIGURE 2 Industry Value Chain Analysis — Chemotherapy Market |
FIGURE 3 Porter's Five Forces Analysis — Chemotherapy Market |
FIGURE 4 Global Chemotherapy Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Chemotherapy Market Share, by Drug Class, 2025 (%) |
FIGURE 6 Chemotherapy Market Share, by Route of Administration, 2025 (%) |
FIGURE 7 Chemotherapy Market Share, by Indication, 2025 (%) |
FIGURE 8 Chemotherapy Market Share, by Age Group, 2025 (%) |
FIGURE 9 Regional Revenue Share — Chemotherapy Market, 2025 (%) |
FIGURE 10 North America Chemotherapy Market Share, by Country, 2025 (%) |
FIGURE 11 Europe Chemotherapy Market Share, by Country, 2025 (%) |
FIGURE 12 Asia-Pacific Chemotherapy Market Share, by Country, 2025 (%) |
FIGURE 13 Competitive Landscape — Market Share of Top 10 Players, 2025 (%)

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Drug Class	Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Others	Alkylating Agents (40.8% share, 2025)	Antimetabolites (10.75% CAGR)
Route of Administration	Oral, Intravenous, Others	Oral (54.3% share, 2025)	Intravenous (10.85% CAGR)
Indication	Blood Cancers, Breast Cancer, Lung Cancer, Others	Lung Cancer (27.8% share, 2025)	Breast Cancer (10.95% CAGR)
Age Group	Adults, Geriatric, Pediatric	Adults (59.8% share, 2025)	Geriatric (11.05% CAGR)
Region	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America (41.2% share, 2025)	Asia-Pacific (11.14% CAGR)

Market Segmentation Overview

By Drug Class

Sub-Segment	Key Trend
Alkylating Agents	Patent-expired cost advantage sustains dominant procurement volumes across public-health systems.
Antimetabolites

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”